Table 5.

Summary of the COLUMBUS efficacy results along with the reported dermatologic adverse events^a.

Study group			Encorafenib plus binimetinib		Encorafenib		Vemurafenib
Overall survival
	Value, median (months)	33.6		23.5		16.9
	HRb	0.61c		0.76d		N/Ae
Progression-free survival
	Value, median (months)	14.9		9.6		7.3
	HR	0.51c		0.68d		N/A
Adverse events (all grade), %			98.4		99.5		100
Adverse events (grade ≥3), %			68.2		67.7		65.6
Dermatologic adverse events
	Rash (all grade), %	16.1		20.8		30.1
	Rash (grade ≥3), %	1.6		2.1		3.2
	Pruritus (all grade), %	12.5		21.9		10.8
	Pruritus (grade ≥3), %	0.5		0.5		0
	Hyperkeratosis (all grade), %	15.1		40.1		29
	Hyperkeratosis (grade ≥3), %	0.5		3.6		0
	Dry skin (all grade), %	16.1		30.2		23.1
	Dry skin (grade ≥3), %	0		0.5		0
	Alopecia (all grade), %	14.6		56.3		37.6
	Alopecia (grade ≥3), %	0		0		0
	Palmoplantar erythrodysesthesia syndrome (all grade), %	7.3		51.6		14
	Palmoplantar erythrodysesthesia syndrome (grade ≥3), %	0		13.5		1.1
	Photosensitivity (all grade), %	3.6		3.6		25.3
	Photosensitivity (grade ≥3), %	0.5		0		1.1
	Palmoplantar keratoderma (all grade), %	9.9		26.6		17.7
	Palmoplantar keratoderma (grade ≥3), %	0		2.1		1.1
	Keratosis pilaris (all grade), %	4.7		3.6		25.3
	Keratosis pilaris (grade ≥3), %	0.5		0		1.1
	Papillomaf (all grade), %	7		10		19
	Papillomaf (grade ≥3), %	N/A		N/A		N/A
	Squamous cell carcinomaf (all grade), %	3		8		17
	Squamous cell carcinomaf (grade ≥3), %	N/A		N/A		N/A
	Basal cell carcinomaf (all grade), %	2		1		2
	Basal cell carcinomaf (grade ≥3), %	N/A		N/A		N/A

^aAdapted from Ascierto et al [15] and Gogas et al [20].

^bHR: hazard ratio.

^cEncorafenib plus binimetinib versus vemurafenib.

^dEncorafenib versus vemurafenib.

^eN/A: not applicable.

^fThese dermatologic adverse events were reported separately by Gogas et al [20] as all grade dermatologic adverse events with no further breakdown.